2024
Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Kidney Outcomes across Baseline Cardiovascular-Kidney-Metabolic Conditions: A Systematic Review and Meta-Analyses.
Siddiqi T, Cherney D, Siddiqui H, Jafar T, Januzzi J, Khan M, Levin A, Marx N, Rangaswami J, Testani J, Usman M, Wanner C, Zannad F, Butler J. Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Kidney Outcomes across Baseline Cardiovascular-Kidney-Metabolic Conditions: A Systematic Review and Meta-Analyses. Journal Of The American Society Of Nephrology 2024 PMID: 39230974, DOI: 10.1681/asn.0000000000000491.Peer-Reviewed Original ResearchSodium-glucose cotransporter-2 inhibitorsType 2 diabetes mellitusChronic kidney diseaseEffects of sodium-glucose cotransporter-2 inhibitorsComposite kidney endpointCotransporter-2 inhibitorsKidney outcomesHeart failureKidney diseaseKidney endpointsHazard ratioDoubling of serum creatinineCombination of heart failureSustained doubling of serum creatininePlacebo-controlled trialReduced ejection fractionBaseline heart failureConfidence intervalsRandom-effects modelAlbuminuria progressionEjection fractionSerum creatinineReview ManagerMellitusPatientsPeak Tricuspid Regurgitation Jet Velocity and Kidney Outcomes in Patients With Heart Failure With Preserved Ejection Fraction
Oka T, Tighiouart H, McCallum W, Tuttle M, Testani J, Sarnak M. Peak Tricuspid Regurgitation Jet Velocity and Kidney Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. Kidney International Reports 2024, 9: 3035-3044. PMID: 39430198, PMCID: PMC11489825, DOI: 10.1016/j.ekir.2024.07.009.Peer-Reviewed Original ResearchLeft ventricular ejection fractionPulmonary artery pressureCreatinine doublingEGFR declineEjection fractionKidney outcomesHeart failurePeak tricuspid regurgitant jet velocityDoubling of serum creatinineTricuspid regurgitant jet velocityElevated pulmonary artery pressureAssociated with lower eGFRWorsening kidney functionVentricular ejection fractionRegurgitant jet velocityCox proportional hazards modelsProportional hazards modelPost hoc analysisBaseline eGFRSerum creatinineLow eGFRTOPCAT trialFollow-upKidney functionArterial pressure
2023
Association of Pulmonary Arterial Pulsatility Index (PAPi) with Kidney Outcomes Among Patients Admitted for Acute Decompensated Heart Failure
Tuttle M, Tighiouart H, Testani J, Banlengchit R, Moises A, Sarnak H, Oka T, Kiernan M, Sarnak M, McCallum W. Association of Pulmonary Arterial Pulsatility Index (PAPi) with Kidney Outcomes Among Patients Admitted for Acute Decompensated Heart Failure. Journal Of The American Society Of Nephrology 2023, 34: 144-145. DOI: 10.1681/asn.20233411s1144d.Peer-Reviewed Original Research
2021
Rates of Reversal of Volume Overload in Hospitalized Acute Heart Failure: Association With Long-term Kidney Function
McCallum W, Tighiouart H, Testani JM, Griffin M, Konstam MA, Udelson JE, Sarnak MJ. Rates of Reversal of Volume Overload in Hospitalized Acute Heart Failure: Association With Long-term Kidney Function. American Journal Of Kidney Diseases 2021, 80: 65-78. PMID: 34843844, PMCID: PMC9135960, DOI: 10.1053/j.ajkd.2021.09.026.Peer-Reviewed Original ResearchConceptsB-type natriuretic peptideAcute heart failureEGFR declineHeart failureVolume overloadKidney functionNatriuretic peptideLower riskN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideHeart Failure Outcome StudyLong-term kidney functionG4-G5Adverse kidney outcomesClinical congestion scoreKidney function declineGlomerular filtration rateCause-specific hazards modelKidney outcomesTolvaptan (EVEREST) trialCardiovascular outcomesVasopressin AntagonismImproved survivalFunction declineDecreased riskAssociation Between Rates of In-Hospital Decongestion Among Patients with Heart Failure with Reduced Ejection Fraction with Longer-Term Kidney Outcomes
McCallum W, Tighiouart H, Testani J, Griffin M, Konstam M, Udelson J, Sarnak M. Association Between Rates of In-Hospital Decongestion Among Patients with Heart Failure with Reduced Ejection Fraction with Longer-Term Kidney Outcomes. Journal Of The American Society Of Nephrology 2021, 32: 687-687. DOI: 10.1681/asn.20213210s1687c.Peer-Reviewed Original ResearchGlucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes
Inzucchi SE, Peixoto AJ, Testani JM. Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes. New England Journal Of Medicine 2021, 385: 669-672. PMID: 34379938, DOI: 10.1056/nejmc2107340.Commentaries, Editorials and Letters